2. Metabolic Enzyme/Protease
  3. Acyltransferase
  4. BW813U

BW813U is a blood-brain barrier-permeable choline acetyltransferase (ChAT) inhibitor. BW813U reduces acetylcholine secretion, decreases cancer cell viability, and slows tumor growth rate. BW813U alters reference memory and causes working memory dysfunction. BW813U shows a synergistic effect with age factors in memory deficits of rats. BW813U can be used in studies related to Alzheimer's disease and lung cancer.

For research use only. We do not sell to patients.

BW813U

BW813U Chemical Structure

CAS No. : 774142-74-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BW813U Related Antibodies

Top Publications Citing Use of Products

View All Acyltransferase Isoform Specific Products:

View All Isoforms
ACAT1 ACAT2 MGAT2 ACAT DGAT1 DGAT2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BW813U is a blood-brain barrier-permeable choline acetyltransferase (ChAT) inhibitor. BW813U reduces acetylcholine secretion, decreases cancer cell viability, and slows tumor growth rate. BW813U alters reference memory and causes working memory dysfunction. BW813U shows a synergistic effect with age factors in memory deficits of rats. BW813U can be used in studies related to Alzheimer's disease and lung cancer[1][2][3].

In Vitro

BW813U potently reduces the viability of human SCC-L and LAC cell lines in vitro in a concentration-dependent manner[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BW813U Related Antibodies
In Vivo

BW813U (25-100 mg/kg/100 μM; i.p./bilateral intracranial injection; single injection) rapidly, dose-dependently and persistently inhibits brain ChAT activity in healthy male Sprague-Dawley rats[1].
BW813U (2.5 mg/kg; i.p.; three times per week) potently reduces the growth rate of xenografted H838 human lung adenocarcinoma tumors in athymic mice without causing obvious toxicity[2].
BW813U (100 mg/kg; i.p.; single administration) causes a synergistic prolongation of peak latency in rats with increasing age, indicating impaired reference memory; it also eliminates memory retention of pre-gap signal duration in the PI-GAP test, indicating impaired working memory for temporal information[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 325-375 g at study start)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg; 100 μM
Administration: i.p.; single injection; intracranial (bilateral); single injection
Result: Caused 60% decrease in cortex, 48% decrease in hippocampus, and 70% decrease in caudate nucleus ChAT activity 1 hour post-injection.
Caused a rapid decrease in ChAT activity, with 45% decrease in cortex and 55% decrease in hippocampus at day 1, persisting (with partial recovery) through day 19.
Caused 78% decrease in cortex, 68% decrease in hippocampus, and 85% decrease in caudate nucleus ChAT activity 1 hour post-injection.
Caused sustained ChAT inhibition for 1 week post-injection.
Animal Model: Athymic mice[2]
Dosage: 2.5 mg/kg
Administration: i.p.; thrice a week
Result: Robustly decreased the growth rate of H838 human LAC tumors.
No gross toxicity, behavioral discomfort, or differences in body weight, food consumption, or water consumption were observed between BW813U-treated and vehicle-treated mice.
Animal Model: Charles River CD (male, mature: 6-10 months, ~400 g; aged: 26-30 months, ~400 g)[3]
Dosage: 100 mg/kg
Administration: i.p.; single injection
Result: Increased mean peak time to 22.3 s in mature rats (vs 20.6 s in vehicle controls) in post-drug PI testing.
Increased mean peak time to 30.25 s in aged rats (vs 24.6 s in vehicle controls) in post-drug PI testing.
Increased mean peak time on gap trials by 15.8 s in mature rats (vs 6.0 s in vehicle controls) in post-drug PI-GAP testing.
Increased mean peak time on gap trials by 16.4 s in aged rats (vs 6.5 s in vehicle controls) in post-drug PI-GAP testing.
Showed no significant differences in peak rate and coefficient of variation measures compared to vehicle groups in post-drug PI testing.
Showed no significant differences in peak rate measures between probe trials with and without gaps.
Molecular Weight

263.76

Formula

C15H18ClNO
CAS No.
SMILES

ClC1=CC=CC(/C=C/C2=NC(C)(C)CC(C)O2)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BW813U Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BW813U774142-74-4AcyltransferaseDiacylglycerol acyltransferaseDiglyceride acyltransferaseacyl-CoA:cholesterol acyltransferasemono- acylglycerol acyltransferasecholine acetyltransferasehuman SCC-L cell lineepithelial-mesenchymal transitionlung cancermonoamine oxidaseAlzheimer’s diseaseblood-brain barrierhuman LAC cell lineacetylcholineacetylcholinesteraseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BW813U
Cat. No.:
HY-183572
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.